Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 12/2010

01-12-2010 | Original paper

Statins and pancreatic cancer risk: a nested case–control study

Authors: Marie C. Bradley, Carmel M. Hughes, Marie M. Cantwell, Liam J. Murray

Published in: Cancer Causes & Control | Issue 12/2010

Login to get access

Abstract

Objective

To investigate the relationship between statin use and pancreatic cancer risk.

Methods

A nested case–control study was conducted within the UK GPRD. Cases had a diagnosis of primary malignant neoplasia of the exocrine pancreas. Controls were matched with cases on general practice site, sex and year of birth. Exposure of interest was exposure to statins since entry into the GPRD until 1 year before the case diagnosis date. Conditional logistic regression analyses were used to generate ORs and 95% CI associated with statin use compared to non-use.

Results

A total of 1,141 pancreatic cancer cases and 7,954 controls were identified. Any use of a statin since entry into the GPRD (excluding the year prior to diagnosis) was not associated with the risk of pancreatic cancer OR 0.93 (95% CI, 0.76–1.14). Neither dose nor duration of statin use affected pancreatic cancer risk. When dose and duration of statin use combined were assessed, no evidence of reduced risk was seen for long-term users of high-dose statins OR 0.71 (0.42–1.20). Statin type (simvastatin vs atorvastatin) was not associated with pancreatic cancer risk.

Conclusion

Statin use at doses for managing hypercholesterolaemia, in a UK population, was not associated with the risk of exocrine pancreatic cancer.
Literature
1.
Jemal A, Uegg L, Ward E (2004) Annual report to the Nation on the status of cancer 1975–2001 with a special feature regarding survival. Cancer 101:3–27CrossRefPubMed
2.
Anderson KE, Potter J, Mack T (2006) Pancreatic cancer. In: Schottenfeld D, Fraumeni JF (eds) Cancer epidemiology and prevention. Oxford University Press, New York, pp 721–762CrossRef
3.
Jemal A, Siegel R, Ward E, Murray T, XU J, Thun M (2007) Cancer statistics 2007. CA Cancer J Clin 57:43–66CrossRefPubMed
4.
5.
Stamm JA, Ornstein DL (2005) The role of statins in cancer prevention and treatment. Oncology (Williston Park) 19:739–750
6.
Vitek L, Lenicek M (2006) Cytoprotective and antiproliferative effects of HMG-CoA reductase inhibitors. Current Enzyme Inhibition 2:261–280CrossRef
7.
Keyomarsi K, Sandoval L, Band V, Pardee AB (1991) Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 51:3602–3609PubMed
8.
Wong WW, Dimitroulakos J, Minden MD, Penn LZ (2002) HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16:508–519CrossRefPubMed
9.
Kaushal V, Kohli M, Mehta P, Mehta JL (2003) Potential anticancer effects of statins: fact or fiction? Endothelium 10:49–58CrossRefPubMed
10.
Sleijfer S, Van Der Gaast A, Planting AST, Stoter G, Verweij J (2005) The potential of statins as part of anti-cancer treatment. Eur J Cancer 41:516–522CrossRefPubMed
11.
Blais L, Desgagne A, LeLorier J (2000) 3-Hydroxy-3-methylglutaryl coenzyme a reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 160:2363–2368CrossRefPubMed
12.
Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO, Sorensen HT, Olsen JH (2005) Cancer risk among statin users: a population-based cohort study. Int J Cancer 114:643–647CrossRefPubMed
13.
Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ (2004) The risk of cancer in users of statins. J Clin Oncol 22:2388–2394CrossRefPubMed
14.
Cauley JA, Zmuda JM, Lui LY, Hillier TA, Ness RB, Stone KL, Cummings SR, Bauer DC (2003) Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health (Larchmt) 12:749–756CrossRef
15.
Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A, Farris PE (2005) Statins and prostate cancer risk: a case-control study. Am J Epidemiol 162:318–325CrossRefPubMed
16.
Khurana V, Bejjanki HR, Caldito G, Owens MW (2007) Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 131:1282–1288CrossRefPubMed
17.
Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G (2005) Statins and the risk of colorectal cancer. N Engl J Med 352:2184–2192CrossRefPubMed
18.
Dale KM, Coleman CI, Henyan NN, Kluger J, White CM (2006) Statins and cancer risk: a meta-analysis. JAMA 295:74–80CrossRefPubMed
19.
Bonovas S, Filioussi K, Tsavaris N, Sitaras NM (2006) Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 24:4808–4817CrossRefPubMed
20.
Bonovas S, Filioussi K, Sitaras NM (2008) Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies. Am J Gastroenterol 103:2646–2651CrossRefPubMed
21.
Khurana V, Sheth A, Caldito G, Barkin JS (2007) Statins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veterans. Pancreas 34:260–265CrossRefPubMed
22.
Kaye JA, Jick H (2004) Statin use and cancer risk in the general practice research database. Br J Cancer 90:635–637CrossRefPubMed
23.
Walley T, Folino-Gallo P, Stephens P, Van Ganse E (2005) Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997–2003. Br J Clin Pharmacol 60:543–551CrossRefPubMed
24.
Walley T, Folino-Gallo P, Schwabe U, Van Ganse E (2004) Variations and increase in use of statins across Europe: data from administrative databases. BMJ 328:385–386CrossRefPubMed
25.
Hollowell J (1997) The general practice research database: quality of morbidity data. Popul Trends 87:36–40PubMed
26.
Garcia Rodriguez LA, Perez Gutthann S (1998) Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol 45:419–425CrossRefPubMed
27.
Jick H, Jick SS, Derby LE (1991) Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 302:766–768CrossRefPubMed
28.
Jick H, Terris BZ, Derby LE, Jick SS (1992) Further validation of information recorded on a general practicioner based computerised data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1:347–349CrossRef
29.
Van Staa T, Abenhaim L (1994) The quality of information recorded on a UK database of primary care records: a study of hospitalizations due to hypoglycaemia and other conditions. Pharmacoepidemiol Drug Saf 3:15–21CrossRef
30.
Kinnear H, Gavin A, Mole D, Ranaghan L (2005) Cancer services audit 2001, pancreas. N Ireland Cancer Registry 1:30
31.
British Medical Association and Royal Pharmaceutical Society of Great Britain (2008) British National formulary 55:140–143
32.
33.
Yang YX, Hennessy S, Propert K, Hwang WT, Sedarat A, Lewis JD (2007) Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 133:748–754CrossRefPubMed
34.
35.
LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK (2005) Treating to new targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425–1435CrossRefPubMed
36.
The Post Coronary Bypass Graft Trial Investigators (1997) The effect of aggressive lowering of low density lipoprotein, cholesterol levels and low dose anti-coagulation on obstructive changes in sapherous-vein coronary-artery bypass grafts. N Engl J Med 336:153–162CrossRef
37.
Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN et al (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291:1071–1080CrossRefPubMed
38.
Clearfield M, Downs JR, Weis S, Whitney EJ, Kruyer W, Shapiro DR, Stein EA, Langendorfer A, Beere PA, Gotto AM (2001) Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Womens Health Gend Based Med 10:971–981CrossRefPubMed
39.
Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, Pedersen TR, Kjekshus J (2004) Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364:771–777CrossRefPubMed
40.
Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B (2002) Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287:3215–3222CrossRefPubMed
41.
Gbelcova H, Lenicek M, Zelenka J, Knejzlik Z, Dvorakova G, Zadinova M, Pouckova P, Kudla M, Balaz P, Ruml T, Vitek L (2008) Differences in antitumor effects of various statins on human pancreatic cancer. Int J Cancer 122:1214–1221CrossRefPubMed
42.
Dorais M, Tamaz R, Rakel A, Lelorrier J, Panzini B (2007) Statins, nsaids and pancreatic cancer. Poster presented at the 23rd International conference in Pharmacoepidemiology 2007 19–22 Aug, Quebec City, Canada. Available in Pharmacoepidemiol Drug Saf 16 (Suppl 2): s93-Abstract 195
43.
Coogan PF, Rosenberg L, Strom BL (2007) Statin use and the risk of 10 cancers. Epidemiology 18:213–219CrossRefPubMed
44.
Graaf MR, Beiderbeck AB, Egberts ACG, Richel DJ, Guchelaar H (2004) The risk of cancer in users of statins. J Clin Oncol 22:2388–2394CrossRefPubMed
45.
Olsen JH, Johansen C, Sorensen HT, McLaughlin JK, Mellemkjaer L, Steffensen FH, Fraumeni JF Jr (1999) Lipid-lowering medication and risk of cancer. J Clin Epidemiol 52:167–169CrossRefPubMed
Metadata
Title
Statins and pancreatic cancer risk: a nested case–control study
Authors
Marie C. Bradley
Carmel M. Hughes
Marie M. Cantwell
Liam J. Murray
Publication date
01-12-2010
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 12/2010
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-010-9628-0

Other articles of this Issue 12/2010

Cancer Causes & Control 12/2010 Go to the issue

Original paper

Association between body mass index and mortality in patients with glioblastoma mutliforme

Original paper

Exogenous sex hormone use and risk of meningioma: a population-based case–control study in Finland

Original paper

Light at night and breast cancer risk: results from a population-based case–control study in Connecticut, USA

Original paper

Association between human papillomavirus and adenocarcinoma of rectum and recto-sigmoid junction: a cohort study of 10,612 women in Taiwan

Editorial

Comprehensive cancer control in the United States: progress and opportunity

Original paper

Body size and the risk of ovarian cancer by hormone therapy use in the California Teachers Study cohort
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits